Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07000357 · ClinicalTrials.gov registry record · Phase 3

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

A Phase 3 study of Cardiovascular Disease, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
15,100
Enrollment target
20
Study locations

NCT07000357 is a Phase 3 study of Cardiovascular Disease that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 15,100 participants, above the 2,603-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (480% higher). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07000357, a Phase 3 study of Cardiovascular Disease, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
15,100 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the final visit for each participant in the study.

Conditions Studied

Cardiovascular Disease

Interventions

  • DRUG Placebo
  • DRUG AZD0780

Study Locations (20)

Arizona

  • Research Site - Gilbert
  • Research Site - Glendale
  • Research Site - Mesa
  • Research Site - Peoria
  • Research Site - Phoenix
  • Research Site - Phoenix
  • Research Site - Phoenix
  • Research Site - Scottsdale
  • Research Site - Tempe
  • Research Site - Tucson
  • Research Site - Tucson
  • Research Site - Tucson

Alabama

  • Research Site - Birmingham
  • Research Site - Fairhope
  • Research Site - Foley
  • Research Site - Huntsville
  • Research Site - Mobile
  • Research Site - Saraland
  • Research Site - Vestavia Hills

California

  • Research Site - Beverly Hills

Trial Details

FieldValue
Enrollment Target 15,100 participants
Start Date 2025-06-04
Est. Completion 2029-10-26
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07000357

The ClinicalTrials.gov registry entry for NCT07000357 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 15,100 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,603-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (480% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07000357 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT07000357 about?

NCT07000357 is a clinical study titled "A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event". The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs pl...

What is the current status of trial NCT07000357?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 15,100 participants. The study started on 2025-06-04. Estimated completion is 2029-10-26.

What conditions does trial NCT07000357 study?

This clinical trial studies the following conditions: Cardiovascular Disease.

What interventions are being tested in trial NCT07000357?

The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG).

Who is sponsoring clinical trial NCT07000357?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07000357 being conducted?

This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cardiovascular Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.